Condition: Venous Leg Ulcers · Sponsor: Skye Biologics Holdings, LLC
The main purpose of this research study is to compare the proportion of wound closure in subjects that receive E-GRAFT™ with SOC versus FIBRACOL™ with SOC. Other research purposes include the following: * Rate of wound closure * Change in ulcer size over 12 weeks * Any adverse events or reactions (side effects) * Change in pain levels * Occurrence of infection
This description comes directly from the study's public registry record.
Adam Isaac, DPM · (301) 471-8378 · aisaacdpm@gmail.com
Melissa Crosswhite · Mcrosswhite@periedu.com
Always discuss trial participation with your own doctor first.
| Professional Education and Research Institute | Roanoke, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06764953